Qurient Co Ltd (115180)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Qurient Co Ltd (115180) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013512
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:韓国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Qurient Co Ltd (Qurient) is a biotechnology company that focuses on the development of new drugs for unmet medical needs. The company’s portfolio of pipeline products includes Q301, Q203, Q701, 5LO INH and CDK7 INH among others. The company is developing products for the treatment of atopic dermatitis; extensively drug-resistant tuberculosis (XDR)/multi drug resistant (MDR)/ totally drug resistant (TDR) tuberculosis (TB); asthama and cancer. It works in partnership with research institutes, CRO, research hospitals, and CMO for research and development of new therapeutics. Qurient is headquartered in Seongnam, Gyeonggi, South Korea.

Qurient Co Ltd (115180) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Qurient Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Qurient Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Qurient Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Qurient Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Qurient Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Qurient Co Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Qurient Raises USD15.5 Million in Series F Venture Financing 10
Qurient Raises USD3 Million in Series E Venture Financing 12
Qurient Raises US$4 Million In Venture Financing 13
Quro Science Secures US$1 Million In Venture Financing 14
Partnerships 15
Qurient Enters into Agreement with Lead Discovery Center 15
Licensing Agreements 16
Qurient Enters Into Licensing Agreement with Max Planck Society and Lead Discovery Center 16
Lead Discovery Center Enters into Licensing Agreement with Qurient 17
Infectex Enters Into Licensing Agreement With Qurient For Tuberculosis Drug Q203 18
Max Planck Institute of Biochemistry And Lead Discovery Center Enter Into Licensing Agreement With Qurient For Kinase Inhibitor 19
Equity Offering 21
Qurient Raises USD25.7 Million in IPO 21
Qurient Co Ltd – Key Competitors 22
Qurient Co Ltd – Key Employees 23
Qurient Co Ltd – Locations And Subsidiaries 24
Head Office 24
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25

List of Tables
Qurient Co Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Qurient Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Qurient Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Qurient Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Qurient Co Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Qurient Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Qurient Raises USD15.5 Million in Series F Venture Financing 10
Qurient Raises USD3 Million in Series E Venture Financing 12
Qurient Raises US$4 Million In Venture Financing 13
Quro Science Secures US$1 Million In Venture Financing 14
Qurient Enters into Agreement with Lead Discovery Center 15
Qurient Enters Into Licensing Agreement with Max Planck Society and Lead Discovery Center 16
Lead Discovery Center Enters into Licensing Agreement with Qurient 17
Infectex Enters Into Licensing Agreement With Qurient For Tuberculosis Drug Q203 18
Max Planck Institute of Biochemistry And Lead Discovery Center Enter Into Licensing Agreement With Qurient For Kinase Inhibitor 19
Qurient Raises USD25.7 Million in IPO 21
Qurient Co Ltd, Key Competitors 22
Qurient Co Ltd, Key Employees 23

★海外企業調査レポート[Qurient Co Ltd (115180)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • RIKEN:製薬・医療:M&Aディール及び事業提携情報
    Summary RIKEN is a research organization that carries out basic and applied science research programs. The organization’s research system consists of strategic research centers, research infrastructure centers, chief scientist system, etc. and a cluster for industry partnerships. Its centers, resear …
  • L’Oreal USA, Inc.:企業の戦略的SWOT分析
    L'Oreal USA, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Star Phoenix Group Ltd (STA):企業の財務・戦略的SWOT分析
    Star Phoenix Group Ltd (STA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Biosynex SA (ALBIO):医療機器:M&Aディール及び事業提携情報
    Summary Biosynex SA (Biosynex), formerly All Diag Sarl is an in-vitro diagnostic company that manufactures, research, and develops rapid diagnostic tests. The company offers rapid diagnostic kits for diagnostic applications; and designing, self-measurement, and distributing thermometers. It offers t …
  • Celanese Corp (CE):企業の財務・戦略的SWOT分析
    Celanese Corp (CE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Asian Citrus Holdings Ltd. (73):企業の財務・戦略的SWOT分析
    Asian Citrus Holdings Ltd. (73) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Abu Dhabi National Energy Co (TAQA):石油・ガス:M&Aディール及び事業提携情報
    Summary Abu Dhabi National Energy Company (TAQA), a subsidiary of government-owned Abu Dhabi Water and Electricity Authority, is an energy and water company. It undertakes power generation; exploration, development, production and storage of oil and gas; pipelines and gas storage; and water desalina …
  • Milestone Scientific Inc (MLSS):企業の財務・戦略的SWOT分析
    Summary Milestone Scientific Inc (Milestone Scientific) is a medical device company that designs, manufactures and distributes computer controlled drug delivery instruments in the medical and dental fields. The company’s medical specialties include anesthesiology, pain medicine, orthopedic surgery, …
  • Powszechny Zaklad Ubezpieczen Group:企業の戦略・SWOT・財務情報
    Powszechny Zaklad Ubezpieczen Group - Strategy, SWOT and Corporate Finance Report Summary Powszechny Zaklad Ubezpieczen Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Capital City Bank Group Inc:企業の戦略・SWOT・財務分析
    Capital City Bank Group Inc - Strategy, SWOT and Corporate Finance Report Summary Capital City Bank Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Shutterfly Inc:企業の戦略的SWOT分析
    Shutterfly Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Xcel Energy Inc (XEL):企業の財務・戦略的SWOT分析
    Xcel Energy Inc (XEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Koch Enterprises, Inc.:企業の戦略的SWOT分析
    Koch Enterprises, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Mycenax Biotech Inc (4726):企業の財務・戦略的SWOT分析
    Summary Mycenax Biotech Inc (Mycenax) is a biopharmaceutical company that develops and manufactures pharmaceutical formulations. The company provides pipeline portfolio encompasses investigational candidates targeted at the treatment of plaque psoriasis, glioblastoma, asthma, adult crohn's Disease, …
  • China Investment Corp:企業のM&A・事業提携・投資動向
    China Investment Corp - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's China Investment Corp Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • NewMarket Corp (NEU):企業の財務・戦略的SWOT分析
    NewMarket Corp (NEU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • CooperSurgical Inc:企業のM&A・事業提携・投資動向
    CooperSurgical Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's CooperSurgical Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • McAfee, Inc.:企業の戦略的SWOT分析
    McAfee, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • CanBas Co Ltd (4575)-製薬・医療分野:企業M&A・提携分析
    Summary CanBas Co Ltd (CanBas) is a clinical stage biopharmaceutical company that provides drugs. The company discovers and develops of novel therapeutics in the field of oncology targeting the cell cycle. It product under development is CBP501, a modified synthetic peptide enhancing the efficacy of …
  • Orly International, Inc.:企業の戦略・SWOT・財務情報
    Orly International, Inc. - Strategy, SWOT and Corporate Finance Report Summary Orly International, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆